Dr. Martin Makary has resigned from the FDA rather than be let go, according to multiple media reports citing unnamed ...

Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug discovery engine by raising ...

Lawmakers in the EU have reached a provisional agreement to strengthen the bloc's critical medicine supply chain and avert the risk of shortages amid rising geopolitical tensions. The Critical ...

Bristol Myers Squibb has forged close ties with China's Hengrui Pharma, partnering across 13 programmes in oncology, haematology, and immunology in a deal that could be worth a massive $15.2 billion.

Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit, which was wound down ...

Novo Nordisk has identified a group of early responders to its high-dose Wegovy formulation that shed almost 28% of their weight in its flagship STEP UP trial. The new analysis, presented at the ...

A doctor by training, Matthew Goodman studied medicine in the UK before specialising in general surgery. He began his career ...

The lengthy appraisal – which has extended for almost two years – was delayed while Italfarmaco subsidiary ITF Pharma and NHS ...

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, has announced the successful closing of an $11.6 ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion. The wide-ranging ...

Bayer has stepped up the digital capabilities of its radiology business with the launch of artificial intelligence-based apps for X-ray, MRI and CT imaging. The cloud-hosted platform – called Calantic ...

It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...